The present paper is about the research conducted on the patients with metabolic syndrome and its results of endoscopic treatment of benign prostatic hyperplasia in these patients. It is generally accepted that the size and volume of the prostate gland is the main prognostic factor affecting the intraoperative and postoperative outcomes of endoscopic treatment of BPH. However, with the rapid development of endoscopic instruments and surgical techniques, the size of the prostate tends to have a lesser influence on the outcome of endoscopic BPH treatment. Currently, MS is becoming an increasingly common disease, which in most cases predicts a poor prognosis for treatment of patients with LUTS.
Background: Based on current evidence, it is not clear whether lone hypertension increases the risk for severe illness from COVID-19, or if increased risk is mainly associated with age, obesity and diabetes. The objective of the study was to evaluate whether lone hypertension is associated with increase mortality or a more severe course of COVID-19, and if treatment and control of hypertension mitigates this risk.Methods: This is a prospective multi-center observational cohort study with 30-day outcomes of 9,531 consecutive SARS-CoV-2 PCR-positive patients ≥ 18 years old (41.9 ± 9.7 years, 49.2% male), Uzbekistan, June 1-September 30, 2020. Patients were subclassified according to JNC8 criteria into six blood pressure stages. Univariable and multiple logistic regression was conducted to examine how variables predict outcomes. Results:The 30-days all-cause mortality was 1.18% (n = 112) in the whole cohort. After adjusting for age, sex, history of myocardial infarction (MI), type-2 diabetes, and obesity, none of six JNC8 groups showed any significant difference in all-cause mortality. However, age was associated with an increased risk of 30-days all-cause mortality (OR = 1.09, 95%CI [1.07-1.12], p < 0.001), obesity (OR = 7.18, 95% CI [4.18-12.44], p < 0.001), diabetes (OR 4.18, 95% CI [2.58-6.76], p < 0.001), and history of MI (OR = 2.68, 95% CI [1.67-4.31], p < 0.001). In the sensitivity test, being ≥ 65 years old increased mortality 10. , p < 0.001). Hospital admission was 12.4% (n = 1,183), ICU admission 1.38% (n = 132). The odds of hospitalization increased having stage-2 untreated hypertension (OR = 4.51,, p < 0.001), stage-1 untreated hypertension (OR = 1.97, 95%CI [1.52-2.56], p < 0.001), and elevated blood pressure (OR = 1.82, 95% , p < 0.001). Neither stage-1 nor stage-2 treated hypertension patients were at statistically significant increased risk for hospitalization after adjusting for confounders. Presenting with stage-2 untreated hypertension increased the odds of ICU admission (OR = 3.05,], p = 0.001).Conclusions: Lone hypertension did not increase COVID-19 mortality or in treated patients risk of hospitalization. 2 Shalaeva et al.
Objective:COVID-19 has been identified as a possible risk factor for hypertension. It may be associated with new onset hypertension or aggravate pre-existing hypertension. The objective of the study was to evaluate systolic (SBP) and diastolic blood pressure (DBP) pattern in COVID-19 patients discharged from the hospital and followed for over 3 months.Design and method:This is a prospective single-center observational cohort study of 1442 hospitalized COVID-19 patients including 259 ICU patients followed over 3-months (52.4 ± 12.3 years, 49.8% male) in Uzbekistan January-June 2021. Patients were subclassified according to JNC 8 hypertension stages. For patients who died, the last confirmed BP was used.Results:In the whole cohort, all-cause mortality was 137 (9.5%). At 3-months in ospitalisat patients (no ICU treatment), mean SBP was raised on 7.4 mmHg, DBP 5.7 mmHg compared to the 1st day of admission due to COVID-19, in ICU patients SBP increased by 12.5 mmHg and DBP 7.2 9 mmHg (Table 1). The prevalence of hypertension in the whole cohort subclassified according to JNC8 criteria is presented in Table 2. In the whole cohort at the baseline, according to JNC8, hypertension was detected in 713 (49.4) patients, and by 3-months follow-up new incidence of hypertension was observed in 254 (17.6%) patients. 483 (65%) patients with diagnosed hypertension at the baseline were required to increase the doses of antihypertensive medications after discharge during 3-months follow-up.Conclusions:COVID-19 necessitating ospitalisation is a powerful risk factor for new onset hypertension or for aggravating pre-existing hypertension.
Background. As is known, the modeling of chronic renal failure against the background of diabetic nephropathy is associated with the need to maximally approximate the conditions for its reproduction to the clinical one. Based on the foregoing, the priority in the reproduction of chronic renal failure should come from the modeling of diabetes mellitus, in particular diabetic nephropathy. Purpose To develop an experimental model of chronic renal failure against the background of diabetic nephropathy. Methods. Experimental studies were carried out on rabbits with the choice of the optimal method from 5 series of experiments. The evaluation was carried out according to the abortive course of the process, the development of hyperglycemic coma, the presence of angiodillation and the reproducibility of the model. For morphological studies, tissue samples in the form of pieces of kidney tissue were taken by performing an operation under ether anesthesia. Results. The 3 stages of nephropathy identified by us during the experiment (I - minor, II - moderate and III - severe) testified to the choice of terms for modeling chronic renal failure. The main criteria for a possible period of transition from nephropathy to the development of chronic renal failure is the presence of hyalinosis of microvessels with thickening of the membranes, which indicated the occurrence of irreversible angiogenic changes. This period is defined by us as 40 days of modeling diabetic nephropathy. Conclusion. In the development of chronic renal failure in a model with diabetic nephropathy, both the lack of expression of the angiogenic factor VEGF by podocytes and tubular epithelial cells and the increased expression of the antiangiogenic factor thrombospondin-1 in the renal glomeruli and interstitium play a certain role in the disruption of angiogenesis. Thrombospondin-1 inhibits the proliferation of endothelial cells stimulated by VEGF and oFRF, causing their apoptosis. As a result, the density of glomerular and peritubular capillaries decreases, glomerulosclerosis and interstitial fibrosis develop.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.